5WHR
Discovery of a novel and selective IDO-1 inhibitor PF-06840003 and its characterization as a potential clinical candidate.
Summary for 5WHR
Entry DOI | 10.2210/pdb5whr/pdb |
Descriptor | Indoleamine 2,3-dioxygenase 1, PROTOPORPHYRIN IX CONTAINING FE, (3R)-3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione, ... (4 entities in total) |
Functional Keywords | cancer immunotherapy, small molecule inhibitor, oxidoreductase, oxidoreductase-inhibitor complex, oxidoreductase/inhibitor |
Biological source | Homo sapiens (Human) |
Cellular location | Cytoplasm, cytosol : P14902 |
Total number of polymer chains | 2 |
Total formula weight | 90033.00 |
Authors | Greasley, S.E.,Kaiser, S.E.,Feng, J.L.,Stewart, A. (deposition date: 2017-07-18, release date: 2017-12-27) |
Primary citation | Crosignani, S.,Bingham, P.,Bottemanne, P.,Cannelle, H.,Cauwenberghs, S.,Cordonnier, M.,Dalvie, D.,Deroose, F.,Feng, J.L.,Gomes, B.,Greasley, S.,Kaiser, S.E.,Kraus, M.,Negrerie, M.,Maegley, K.,Miller, N.,Murray, B.W.,Schneider, M.,Soloweij, J.,Stewart, A.E.,Tumang, J.,Torti, V.R.,Van Den Eynde, B.,Wythes, M. Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. J. Med. Chem., 60:9617-9629, 2017 Cited by PubMed: 29111717DOI: 10.1021/acs.jmedchem.7b00974 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.28 Å) |
Structure validation
Download full validation report